u/old_account_2023

been here since it was 40 people and a wiki stub, milestones like this one are exactly why

This is the principle the whole site is built on.

Disagreeing with this bit: making individual cases public by default is worse for the person being moderated.

Yes — nobody here is your clinician, and the good answers on this board all end with that.

the first month is a tolerance check, not a results phase

Disagree with chasing the last stretch by going up. You are trading a real side-effect cost for a number you chose arbitrarily.

Push back: handling advice from one compound does not transfer to another just because both are peptides.

On the thin testing history in this board, and what to do about it.

Most of the compounds discussed here have a handful of independent results across the entire site, and several have none. That is a fact about how few members have paid for testing, not a judgement about the material.

What follows: buy small, test identity first for anything unusual, and post the result even when it is unremarkable. The vendor source pages are built from exactly these submissions, and the compounds with the thinnest coverage are the ones where one more entry changes the picture most. Research material is not approved for human use, so what this board can usefully build is an analytical record.

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

search first, but a repeat question is not a crime

Funding and links, in full, because the question deserves a straight answer.

Sponsor units are labelled as sponsored. Each vendor source page carries one outbound link to that supplier’s own storefront, marked nofollow and sponsored, so you can read their account of themselves against the record on the page. Nothing is received for those links, no supplier pays for a directory position, and no rating is for sale.

No referral or affiliate links are permitted anywhere on the site, from anybody, including in the pricing threads where the temptation is highest. That rule is the reason those threads are worth reading, and it is enforced without exception. The full version of all of this is on the about page and it is deliberately boring.

Correcting my own comment: the storage condition I quoted was for the lyophilised powder, not for solution.

Bought small on anything without a testing history here. That rule has never once cost me anything.

Withdrawal studies in this class consistently show substantial regain after discontinuation. That is a pharmacological finding about a chronic condition, not a statement about anyone’s discipline.

Naming in this space is inconsistent. Several widely used names map to more than one molecule, so a catalogue number and a sequence beat a common name every time.

Spent an evening on the histology scoring system and understood the trial literature far better afterwards.

lyophilised and stored cold is the default for a reason

lyophilised and stored cold is the default for a reason

Same view — strict evidence rules make this board slower and make the archive worth reading in three years.

Chased the last three kilos with a dose increase and got a fortnight of sulphur burps and no change in the number.

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

What is the plan if the drift continues for another month?

MASH endpoints are histological, which is a much harder bar

Disagreeing with this bit: that number comes from a different programme with a different population.

Which phase and which arm are you quoting?

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

For any compound with a thin testing history, identity is the first question. Mass spectrometry against a theoretical mass answers it; an area-percent purity figure does not.

That method was developed for a different compound class and would not resolve the impurities you are asking about.

Small fix — that is net peptide content, not purity. Both are on the certificate and they differ substantially here.

Correction: that name covers two different molecules and the thread has been discussing both as one.

find the dose that holds, then stop optimising

the titration in the trials was slow and deliberate

That figure is from the obesity programme, and this thread is about the hepatic one.

find the dose that holds, then stop optimising

That is an escalation schedule for an unapproved compound and this board does not host those.

Small fix — archiving happens at a year, not at six months. It is in the published policy.

How fast was the escalation in that protocol?

That figure is from the obesity programme, and this thread is about the hepatic one.

Yes — a proposal with concrete wording gets discussed. A complaint about the rules in general does not.

no question is too basic here, that is the entire point of the board

Careful — that would make individual moderation cases public by default, which is worse for the person complaining.

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.